Genomic

Dataset Information

0

A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia


ABSTRACT:

LGL leukemia can be divided into three subsets including the following: αβ or γδT-LGL and NK-LGL leukemia. All three subtypes will be enrolled using a two-stage design. The primary endpoint of the study is assessment of overall clinical response. Correlative laboratory studies will be performed aimed at determining the mechanism of response to treatment. Thirteen participants will be accrued in the first stage at a dose of 300 mg BID administered intermittently every other week (i.e., 7 days on and 7 days off). If there are two or more responders, the protocol will be extended to a second stage of the study and accrual will be extended to 25 evaluable participants. Allowing for 10% rate of ineligibility due to unexpected events and dropout, we will accrue 14 patients in the first stage and 27 patients in total. Participants that withdraw from the study for reason unrelated to toxicity, will be replaced. There are two potential stopping rules for toxicity.

If 3 or more participants out of the 13 enrolled in the first stage experiences grade IV neurotoxicity, the study will be stopped due to excessive toxicity. Dose reductions have been incorporated for hematologic toxicity. Treatment of T and NK LGL leukemia with immunosuppressive agents such as low-dose methotrexate generally require from four to six months for a clinical response and sometimes much longer. Therefore, in participants who show clinical improvement with less than grade three toxicity, tipifarnib treatment will be continued for as many as four additional months (12 months total). After the first 8 months, response will be assessed. The protocol treatment will be discontinued in participants with progression of disease. A long-term follow up will be performed for five years in patients that receive a complete clinical response. The long-term follow up will consist of vital signs, weight, CBCs, serum chemistries, and physical examination at six month intervals.

PROVIDER: phs000594 | dbGaP |

SECONDARY ACCESSION(S): PRJNA188342PRJNA188343

REPOSITORIES: dbGaP

Dataset's files

Source:
Action DRS
GapExchange_phs000594.v1.p1.xml Xml
dbGaPEx2.1.5.xsd Other
phs000594.v1-Documents.zip Other
Study_Report.phs000594.BMF_5402.v1.p1.MULTI.pdf Pdf
manifest_phs000594.BMF_5402.v1.p1.c1.GRU-IRB-PUB.pdf Pdf
Items per page:
1 - 5 of 50

Similar Datasets

2024-09-02 | BIOMD0000000814 | BioModels
2022-03-11 | GSE198136 | GEO
2016-04-05 | E-MTAB-3660 | biostudies-arrayexpress
2021-09-09 | GSE183415 | GEO
2022-01-07 | GSE193157 | GEO
2012-04-11 | E-GEOD-37180 | biostudies-arrayexpress
2012-09-13 | E-GEOD-40837 | biostudies-arrayexpress
2009-04-01 | GSE12062 | GEO
| EGAS00001003178 | EGA
2016-07-04 | PXD003230 | Pride